{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:45:21Z","timestamp":1789429521726,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222902"],"award-info":[{"award-number":["82222902"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54097-1","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:54:44Z","timestamp":1732766084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study"],"prefix":"10.1038","volume":"15","author":[{"given":"Wanchun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-3032","authenticated-orcid":false,"given":"Vincent Ka Chun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwun Kei","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koon Ho","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui Kai","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine Sze Ling","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-1959","authenticated-orcid":false,"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-7808","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther Wai Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian Chi Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-1147","authenticated-orcid":false,"given":"Eric Yuk Fai","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"54097_CR1","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.3390\/ijms23158364","volume":"23","author":"S Attardo","year":"2022","unstructured":"Attardo, S., Musumeci, O., Velardo, D. & Toscano, A. Statins Neuromuscular Adverse Effects. Int J. Mol. Sci. 23, 8364 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"54097_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/jpm12121981","volume":"12","author":"FL Andronie-Cioara","year":"2022","unstructured":"Andronie-Cioara, F. L., Jurcau, A., Jurcau, M. C., Nistor-Cseppento, D. C. & Simion, A. Cholesterol Management in Neurology: Time for Revised Strategies? J. Pers. Med 12, 1981 (2022).","journal-title":"J. Pers. Med"},{"key":"54097_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11883-022-01077-9","volume":"25","author":"WJ Loh","year":"2023","unstructured":"Loh, W. J. & Watts, G. F. The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder. Curr. Atheroscler. Rep. 25, 43\u201353 (2023).","journal-title":"Curr. Atheroscler. Rep."},{"key":"54097_CR4","doi-asserted-by":"publisher","first-page":"e061350","DOI":"10.1136\/bmjopen-2022-061350","volume":"12","author":"JS Guadamuz","year":"2022","unstructured":"Guadamuz, J. S., Shooshtari, A. & Qato, D. M. Global, regional and national trends in statin utilisation in high-income and low\/middle-income countries, 2015-2020. BMJ Open 12, e061350 (2022).","journal-title":"BMJ Open"},{"key":"54097_CR5","unstructured":"PRAC recommendations on signals: Adopted at the 9-12 January 2023 PRAC meeting). European Medicine Agency (2023)."},{"key":"54097_CR6","unstructured":"Medicines and Healthcare products Regulatory Agency. Statins: very infrequent reports of myasthenia gravis) (2023)."},{"key":"54097_CR7","unstructured":"Drug Information Pharmacovigilance Division. Statins: very infrequent reports of myathenia gravis). Department of Health (2023)."},{"key":"54097_CR8","unstructured":"Department of Health and Aged Care. Product Information safety updates - November 2023) (2023)."},{"key":"54097_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency. Summary of Investigation Results: Preparations containing HMG-CoA reductase inhibitor) (2023)."},{"key":"54097_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2021.108788","volume":"701","author":"ML Paz","year":"2021","unstructured":"Paz, M. L. & Barrantes, F. J. Cholesterol in myasthenia gravis. Arch. Biochem Biophys. 701, 108788 (2021).","journal-title":"Arch. Biochem Biophys."},{"key":"54097_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell, L. C. & Levine, J. M. Myasthenic crisis. Neurohospitalist 1, 16\u201322 (2011).","journal-title":"Neurohospitalist"},{"key":"54097_CR12","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. Lancet Reg. Health West Pac. 5, 100063 (2020).","journal-title":"Lancet Reg. Health West Pac."},{"key":"54097_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-4-61","volume":"4","author":"MJ Keogh","year":"2010","unstructured":"Keogh, M. J., Findlay, J. M., Leach, S. & Bowen, J. Statin-associated weakness in myasthenia gravis: a case report. J. Med Case Rep. 4, 61 (2010).","journal-title":"J. Med Case Rep."},{"key":"54097_CR14","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","volume":"63","author":"MS Cartwright","year":"2004","unstructured":"Cartwright, M. S., Jeffery, D. R., Nuss, G. R. & Donofrio, P. D. Statin-associated exacerbation of myasthenia gravis. Neurology 63, 2188 (2004).","journal-title":"Neurology"},{"key":"54097_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","volume":"85","author":"V Purvin","year":"2006","unstructured":"Purvin, V., Kawasaki, A., Smith, K. H. & Kesler, A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Med. (Baltim.) 85, 82\u201385 (2006).","journal-title":"Med. (Baltim.)"},{"key":"54097_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mus.25155","volume":"54","author":"R Khalid","year":"2016","unstructured":"Khalid, R., Ibad, A. & Thompson, P. D. Statins and Myasthenia Gravis. Muscle Nerve 54, 509 (2016).","journal-title":"Muscle Nerve"},{"key":"54097_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3925","volume":"9","author":"E Frasson","year":"2021","unstructured":"Frasson, E. et al. Statin-associated necrotizing autoimmune myopathy with concurrent myasthenia gravis. Clin. Case Rep. 9, e03925 (2021).","journal-title":"Clin. Case Rep."},{"key":"54097_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","volume":"21","author":"J Gale","year":"2014","unstructured":"Gale, J. & Danesh-Meyer, H. V. Statins can induce myasthenia gravis. J. Clin. Neurosci. 21, 195\u2013197 (2014).","journal-title":"J. Clin. Neurosci."},{"key":"54097_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mus.26637","volume":"60","author":"V Gras-Champel","year":"2019","unstructured":"Gras-Champel, V., Batteux, B., Masmoudi, K. & Liabeuf, S. Statin-induced myasthenia: A disproportionality analysis of the WHO\u2019s VigiBase pharmacovigilance database. Muscle Nerve. 60, 382\u2013386 (2019).","journal-title":"Muscle Nerve"},{"key":"54097_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/mus.21074","volume":"38","author":"SJ Oh","year":"2008","unstructured":"Oh, S. J. et al. Statins may aggravate myasthenia gravis. Muscle Nerve. 38, 1101\u20131107 (2008).","journal-title":"Muscle Nerve"},{"key":"54097_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/archinte.166.14.1519","volume":"166","author":"G Tsivgoulis","year":"2006","unstructured":"Tsivgoulis, G. et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch. Intern Med. 166, 1519\u20131524 (2006).","journal-title":"Arch. Intern Med"},{"key":"54097_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/qjmed\/hcs125","volume":"105","author":"GJ McMillan","year":"2012","unstructured":"McMillan, G. J. & Hubbard, R. E. Frailty in older inpatients: what physicians need to know. QJM 105, 1059\u20131065 (2012).","journal-title":"QJM"},{"key":"54097_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jneuroim.2015.10.018","volume":"289","author":"CY Lee","year":"2015","unstructured":"Lee, C. Y. et al. Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese. J. Neuroimmunol. 289, 177\u2013181 (2015).","journal-title":"J. Neuroimmunol."},{"key":"54097_CR24","doi-asserted-by":"publisher","first-page":"h6926","DOI":"10.1136\/bmj.h6926","volume":"352","author":"AY Wong","year":"2016","unstructured":"Wong, A. Y. et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 352, h6926 (2016).","journal-title":"BMJ"},{"key":"54097_CR25","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hernan","year":"2022","unstructured":"Hernan, M. A., Wang, W. & Leaf, D. E. Target Trial Emulation A Framework for Causal Inference From Observational Data. Jama-J. Am. Med Assoc. 328, 2446\u20132447 (2022).","journal-title":"Jama-J. Am. Med Assoc."},{"key":"54097_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0962280211403603","volume":"22","author":"G Danaei","year":"2013","unstructured":"Danaei, G., Rodriguez, L. A., Cantero, O. F., Logan, R. & Hernan, M. A. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat. Methods Med Res. 22, 70\u201396 (2013).","journal-title":"Stat. Methods Med Res"},{"key":"54097_CR27","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354, i4515 (2016).","journal-title":"BMJ"},{"key":"54097_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2337\/dc16-1617","volume":"40","author":"EY Wan","year":"2017","unstructured":"Wan, E. Y. et al. Association of Visit-to-Visit Variability of Systolic Blood Pressure With Cardiovascular Disease and Mortality in Primary Care Chinese Patients With Type 2 Diabetes-A Retrospective Population-Based Cohort Study. Diabetes Care 40, 270\u2013279 (2017).","journal-title":"Diabetes Care"},{"key":"54097_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","volume":"22","author":"EYF Wan","year":"2022","unstructured":"Wan, E. Y. F. et al. Bell\u2019s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect. Dis. 22, 64\u201372 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"54097_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7326\/M22-3057","volume":"176","author":"EYF Wan","year":"2023","unstructured":"Wan, E. Y. F. et al. Effectiveness of Molnupiravir and Nirmatrelvir\u2013Ritonavir in Hospitalized Patients With COVID-19: A Target Trial Emulation Study. Ann. Intern. Med. 176, 505\u2013514 (2023).","journal-title":"Ann. Intern. Med."},{"key":"54097_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M19-3671","volume":"173","author":"WC Lau","year":"2020","unstructured":"Lau, W. C. et al. Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study. Ann. Intern. Med. 173, 1\u20139 (2020).","journal-title":"Ann. Intern. Med."},{"key":"54097_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki, A. 3rd et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55, 16\u201323 (2000).","journal-title":"Neurology"},{"key":"54097_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"key":"54097_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/1536867X0400400403","volume":"4","author":"Z Fewell","year":"2004","unstructured":"Fewell, Z. et al. Controlling for time-dependent confounding using marginal structural models. Stata J. 4, 402\u2013420 (2004).","journal-title":"Stata J."},{"key":"54097_CR35","first-page":"39","volume":"2","author":"EJ Murray","year":"2021","unstructured":"Murray, E. J., Caniglia, E. C. & Petito, L. C. Causal survival analysis: a guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. Res. Methods Med. Health Sci. 2, 39\u201349 (2021).","journal-title":"Res. Methods Med. Health Sci."},{"key":"54097_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0248-6","volume":"16","author":"JS Ngwa","year":"2016","unstructured":"Ngwa, J. S. et al. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. Bmc Med Res Methodol. 16, 148 (2016).","journal-title":"Bmc Med Res Methodol."},{"key":"54097_CR37","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/bcp.14074","volume":"86","author":"R Roller\u2010Wirnsberger","year":"2020","unstructured":"Roller\u2010Wirnsberger, R., Thurner, B., Pucher, C., Lindner, S. & Wirnsberger, G. H. The clinical and therapeutic challenge of treating older patients in clinical practice. Br. J. Clin. Pharmacol. 86, 1904\u20131911 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"54097_CR38","unstructured":"World Health Organization. Decade of healthy ageing: baseline report (2021)."},{"key":"54097_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/mus.27169","volume":"63","author":"A Kim","year":"2021","unstructured":"Kim, A. et al. Risk factors for developing post-thymectomy myasthenia gravis in patients with thymoma. Muscle Nerve 63, 531\u2013537 (2021).","journal-title":"Muscle Nerve"},{"key":"54097_CR40","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/ejcts\/ezx163","volume":"52","author":"L Xue","year":"2017","unstructured":"Xue, L. et al. Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis. Eur. J. Cardio-Thorac. 52, 692\u2013697 (2017).","journal-title":"Eur. J. Cardio-Thorac."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54097-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:12:39Z","timestamp":1732767159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54097-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54097"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54097-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.Y.F.W. has received research grants from the Health Bureau of the Government of the Hong Kong SAR, the Hong Kong Research Grant Council, National Natural Science Foundation of China, outside the submitted work. I.C.K.W. reports research funding from Amgen, Bristol Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council, the Hong Kong Health and Medical Research Fund, the National Institute for Health Research in England, the European Commission, and the National Health and Medical Research Council in Australia, consulting fees from IQVIA and World Health Organisation, payment for expert testimony for Appeal Court of Hong Kong, outside the submitted work; and is a non-executive director of Jacobson Medical in Hong Kong, Advance Data Analytics for Medical Science (ADAMS) Limited (HK), Asia Medicine Regulatory Affairs (AMERA) Services Limited and OCUS Innovation Limited (HK, Ireland and UK) a former director of Therakind in England, outside of the submitted work; I.C.K.W. reports role as member of Pharmacy and Poisons Board in Hong Kong, the Expert Committee on Clinical Events Assessment Following COVID-19 Immunisation, and the Advisory Panel on COVID-19 Vaccines of the Hong Kong Government, outside the submitted work. C.S.L.C. has received grants from the Health Bureau of the Hong Kong Government, the Hong Kong Research Grants Council, the Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen, and personal fees from Prime Vigilance, outside the submitted work. E.W.Y.C. reports honoraria from the Hospital Authority and grants from the Hong Kong Research Grants Council, the Research Fund Secretariat of the Food and Health Bureau, the National Natural Science Fund of China, the Wellcome Trust, Bayer, Bristol Myers Squibb, Pfizer, Janssen, Amgen, Takeda, RGA Reinsurance Company, AstraZeneca, the Narcotics Division of the Security Bureau of Hong Kong Special Administrative Region, Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, Novartis, National Health and Medical Research Council Australia, outside the submitted work. Francisco Tsz Tsun Lai are partially supported by the Laboratory of Data Discovery for Health (D24H) funded by AIR@InnoHK administered by the Innovation and Technology Commission, outside the submitted work. X.L. received research grants from the Research Fund Secretariat of the Health Bureau, Health and Medical Research Fund (HMRF, HKSAR), Health and Medical Research Fund Fellowship Scheme (HMRF Fellowship, HKSAR), Research Grants Council Early Career Scheme (RGC\/ECS, HKSAR), Research Grants Council Research Impact Fund (RGC\/RIF, HKSAR), Commission grants from Hospital Authority of Hong Kong; educational and investigator initiate research fund from Janssen and Pfizer; internal funding from the University of Hong Kong; consultancy fee from Pfizer, Merck Sharp & Dohme, Open Health; she is also the former non-executive director of ADAMS Limited Hong Kong; all outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10317"}}